Summarized by Masters of Longevity from Longevity Technology.
A DSMB issued a second positive safety recommendation for DUET-AD.

Key Takeaways
- A DSMB reviewed interim safety data and recommended continuation.
- DUET‑AD is testing oral buntanetap in early Alzheimer’s patients.
- This second clearance allows dosing but does not show efficacy.



